Immunovant, Inc.
IMVT
$25.75
$0.110.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 12.54% | -4.88% | -13.31% | 4.21% | -1.84% |
| Total Depreciation and Amortization | -3.81% | -1.87% | -1.83% | 10.10% | 11.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -4.80% | -27.80% | 58.29% | 0.29% | -8.18% |
| Change in Net Operating Assets | -47.91% | 168.01% | 3.54% | -1,434.61% | -113.60% |
| Cash from Operations | 9.94% | 12.69% | -6.12% | -10.21% | -13.25% |
| Capital Expenditure | -- | -- | -- | -11.67% | 8.16% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -11.67% | 8.16% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,197.98% | 742.87% | -99.35% | 18,200.77% | 237.53% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2,195.60% | 742.87% | -99.35% | 18,187.82% | 237.53% |
| Foreign Exchange rate Adjustments | -57.06% | 255.12% | -15.98% | -227.52% | -114.20% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 713.50% | 33.04% | -133.91% | 445.31% | -12.85% |